



SCOHIA PHARMA, Inc.

June 17, 2019

**Presentation of New Preclinical Data of SCO-267, a GPR40 agonist, at
The American Diabetes Association's 79th Scientific Sessions**

SCOHIA PHARMA, Inc. gave a poster presentation on SCO-267, a GPR40 agonist, at the 79th Scientific Sessions of American Diabetes Association held June 7-11, 2019 in San Francisco, California, USA. The presentation included findings of SCO-267 on the efficacy and safety in preclinical animal models.

Title

SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control More Than That by Fasiglifam in Rat Models of Diabetes and Obesity

In this presentation, SCO-267 was demonstrated to be a potent GPR40 full agonist and highly effective in improving glucose tolerance compared to fasiglifam, a GPR40 partial agonist, in rats. In addition, once-daily oral dose of SCO-267 was shown to decrease body weight in obese rats. Furthermore, *in vitro* and *in vivo* toxicological studies demonstrated good safety profiles of SCO-267. These results suggest that SCO-267 may induce similar favorable effects in patients with diabetes and obesity.

[**View ePoster**](#)

Contact for inquiries
info@scohia.com